Zobrazeno 1 - 10
of 207
pro vyhledávání: ''
Autor:
Eva Karamitopoulou, Aurélie Pahud de Mortanges, Aurel Perren, Beat Gloor, Andreas Andreou, Marianne Tinguely
Publikováno v:
Cancer Immunology Research. 9:1439-1450
Immunotherapy, including PD-1/PD-L1 agonists, has shown limited efficacy in pancreatic ductal adenocarcinoma (PDAC). We examined the PD-1/PD-L1 expression and immunoarchitectural features by automated morphometric analysis using multiplex immunofluor
Autor:
Martin H. Voss, Ed Reznik, Diego Chowell, Renzo G. DiNatale, Yasuhiro Funahashi, Pallavi Sachdev, Chung-Han Lee, Chirag Krishna, Mark Lee, Kate Weiss, Yukinori Minoshima, Darren R. Feldman, Robert J. Motzer, Doug Hoen, A. Ari Hakimi, Lynda Vuong, Samuel Murray, Luc G. T. Morris, Timothy A. Chan, Ritesh Kotecha, Junji Matsui, Maria I. Carlo, Kenichi Nomoto, Yusuke Adachi, Vladimir Makarov, Cristina Valero
Publikováno v:
Mol Cancer Res
Immune checkpoint blockade (ICB) therapy has substantially improved the outcomes of patients with many types of cancers, including renal cell carcinoma (RCC). Initially studied as monotherapy, immunotherapy-based combination regimens have improved th
Autor:
Xiao Jing Lin, Sai-Juan Chen, Bing Chen, Qing Xue, Bowen Cui, Yu Chen, Bing-Shun Wang, Hongming Zhu, Su-Jiang Zhang, Li Chen, Zhu Chen, Lu Jiang, Hai Fang, Shengyue Wang, Junmin Li, Niu Qiao, Yang Shen
Publikováno v:
Clinical Cancer Research. 27:3683-3694
Purpose: The current stratification system for acute promyelocytic leukemia (APL) is based on the white blood cell (WBC) and the platelet counts (i.e., Sanz score) over the past two decades. However, the borderlines among different risk groups are so
Publikováno v:
Cancer Res
Women with a history of ductal carcinoma in situ (DCIS) have an elevated risk of a subsequent invasive breast cancer, but there are few established potentially modifiable factors known to lower this risk. Bisphosphonates are a commonly used treatment
Autor:
Manisha Palta, Kent J. Weinhold, Brian G. Czito, David M. Brizel, John S. Yi, April K.S. Salama, Christel Rushing, Douglas S. Tyler, Brent A. Hanks, Georgia M. Beasley, David S. Yoo, Paul J. Mosca, Kristen N. Linney, M. Angelica Selim, Chelsae Dumbauld, Katelyn N. Steadman, Walter T. Lee
Publikováno v:
Clin Cancer Res
Purpose:In this prospective trial, we sought to assess the feasibility of concurrent administration of ipilimumab and radiation as adjuvant, neoadjuvant, or definitive therapy in patients with regionally advanced melanoma.Patients and Methods:Twenty-
Autor:
Jessica Hoare, Katrina Purtell, Elizabeth A. Sugar, Raka Bhattacharya, Arsen Osipov, Daniel A. Laheru, Katherine M. Bever, Rose Parkinson, Beth Onner, Matthew J. Weiss, Jin He, Ding Ding, Qingfeng Zhu, Elizabeth M. Jaffee, Guanglan Mo, Elizabeth D. Thompson, Amy Hacker-Prietz, Victoria M. Kim, Martin A. Makary, Hongyan Cai, Barish H. Edil, Richard D. Schulick, Robert A. Anders, John L. Cameron, Joseph M. Herman, Lindsey Manos, Nilofer S. Azad, Christopher L. Wolfgang, Dung T. Le, Dwayne L. Thomas, Jennifer N. Durham, Kevin C. Soares, Carol Judkins, Alex B. Blair, Ana De Jesus-Acosta, Sara Solt, Lei Zheng
Publikováno v:
Clin Cancer Res
Purpose: Immunotherapy is currently ineffective for nearly all pancreatic ductal adenocarcinomas (PDAC), largely due to its tumor microenvironment (TME) that lacks antigen-experienced T effector cells (Teff). Vaccine-based immunotherapies are known t
Autor:
Guanghui Gao, Zhe-Hai Wang, Jifeng Feng, Meijuan Huang, Xinmin Yu, Zhihua Liu, Caicun Zhou, Lihong Wu, Yina Wang, Ying Cheng, Jun Zhao, Yuan Chen, Zhiyong Ma, Weixia Li, Xiaoyan Lin, Shengxiang Ren, Kangsheng Gu, R. Guo, Jun Zhang, Quan Ren Wang, Xinfeng Yang, Gongyan Chen, Yu Yao, Jianxing He, Jianhua Chen, Jianhua Shi
Publikováno v:
Clinical Cancer Research. 27:1296-1304
Purpose: Our preclinical work suggests that appropriate angiogenesis inhibition could potentiate PD-1/PD-L1 blockade via alleviating hypoxia, increasing infiltration of CD8+ T cells and reducing recruitment of tumor-associated macrophages. We hereby
Autor:
Chiara Cremolini, Axel Grothey, Jim Abraham, Donald A. Berry, David D. Halbert, Mohamed E. Salem, Michael J. Hall, Matthew J. Oberley, Anthony Helmstetter, Carlotta Antoniotti, W. Michael Korn, Anthony F. Shields, David Spetzler, John L. Marshall, Alfredo Falcone, Phillip Stafford, Daniel Magee, Joanne Xiu, Heinz-Josef Lenz, Alan P. Venook
Publikováno v:
Clinical Cancer Research. 27:1174-1183
Purpose: FOLFOX, FOLFIRI, or FOLFOXIRI chemotherapy with bevacizumab is considered standard first-line treatment option for patients with metastatic colorectal cancer (mCRC). We developed and validated a molecular signature predictive of efficacy of
Publikováno v:
Cancer Res
The sum of target lesions is routinely used to evaluate patient objective responses to treatment in the RECIST criteria, but it fails to address response heterogeneity across metastases. This study argues that spatiotemporal heterogeneity across meta
Autor:
Run-Cong Nie, Jinyuan Li, Pei-dong Chi, Qian-yi Zhang, Tobias Herold, Wolfgang Hiddemann, Yun Wang, Yong-qing Wang, Xiong Zhang, Yan-Yu Cai, Yu Zhang, Ze-lin Liu, Yang Liang, San-bin Wang, Robert Peter Gale, Yong-zhong Su, Xin Du, Klaus H. Metzeler, Tong-hua Yang, Qing Zhang, Zhe-Yuan Qin, Yun Zeng, Xin-mei Zhang, Yuan-bin Wu, Na Zhong, Jian-wei Wu, Bei Zhang, Zhi-jun Wuxiao, Xue-Yi Pan, Qifa Liu, Zhi-wei Liang, Shun-Qing Wang, Jing-bo Xu, Si-Liang Chen, Bingyi Wu, Ruo-zhi Xiao
Publikováno v:
Clinical Cancer Research. 27:255-266
Purpose: Prediction models for acute myeloid leukemia (AML) are useful, but have considerable inaccuracy and imprecision. No current model includes covariates related to immune cells in the AML microenvironment. Here, an immune risk score was explore